ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Public ClinicalTrials.gov record NCT07294170. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Study identification
- NCT ID
- NCT07294170
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2025
- Primary completion
- Mar 6, 2028
- Completion
- Mar 6, 2028
- Last update posted
- Apr 22, 2026
2025 – 2028
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Profound Research LLC - Carlsbad | Carlsbad | California | 92011 | Recruiting |
| Visionary Investigators Network | Miami | Florida | 33133 | Recruiting |
| Erlanger Health System | Columbia | Maryland | 21044 | Recruiting |
| Dent Neurologic Institute - Amherst | Amherst | New York | 14226 | Recruiting |
| National Neuromuscular Research Institute | Austin | Texas | 78759 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
Recently updated AChR-Ab Seropositive Generalized Myasthenia Gravis trials
Other public records listing AChR-Ab Seropositive Generalized Myasthenia Gravis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07761026: The AXIS Registry is a 10-year Longitudinal Research Initiative That Captures the Real-world Experiences of People Living With Autoimmune Neurology Conditions. Launching in Myasthenia Gravis (MG), we Plan to Evaluate Expansion to Other Conditions Across Autoimmune Neurology. Recruiting
- NCT07673627: ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis Recruiting
- NCT07284420: ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod Recruiting
All AChR-Ab Seropositive Generalized Myasthenia Gravis trials →
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07294170, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 22, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07294170 live on ClinicalTrials.gov.